Videos

Scott Tagawa, MD, MS, FACP, discusses other prostate cancer settings besides metastatic CRPC where Lu 177 vipivotide tetraxetan could potentially be useful, and touches on ongoing clinical trials in these settings.

A discussion of key safety data on the VISION trial.

Scott Tagawa, MD, MS, FACP, compares the use of single-agent regimens versus combination regimens in the treatment of metastatic prostate cancer.

Scott Tagawa, MD, MS, FACP, reviews key efficacy data from the VISION trial of Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (CRPC).

A comprehensive review of treatment options for metastatic prostate cancer, including PSMA-targeted therapies.

Scott Tagawa, MD, MS, FACP expands upon prostate-specific membrane antigen (PSMA)-based PET imaging modalities.

A focused discussion on how phenotypic biomarkers and positron emission tomography (PET)-based imaging can be combined to diagnose and treat prostate cancer.

Scott Tagawa, MD, MS, FACP reviews emerging phenotypic biomarker approaches that may complement genomic biomarker testing.

An overview of genomic biomarker testing approaches for patients with prostate cancer.

Scott Tagawa, MD, MS, FACP, comments on some of the clinical factors that impact diagnosis, prognosis, and treatment of prostate cancer.

Danny Nguyen, MD, discusses next steps for research of mobocertinib in patients with EGFR-positive non–small cell lung cancer.

Shaji Kumar, MD, discusses the current treatment options and unmet needs for patients with newly diagnosed multiple myeloma.

Paul G. Richardson, MD, discusses the latest regulatory movement in the multiple myeloma space.

Solange Peters, MD, PhD, discusses the biomarkers for immunotherapy used in the phase 3 CheckMate 743 trial.

Adam Cohen, MD, discusses his presentation on updates in BCMA-directed therapies for multiple myeloma, which he gave during the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Guenther Koehne, MD, PhD, discusses the exciting presentations going on at the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Pashna Munshi, MD, wraps up by talking about future directions and emerging treatment regimens in the field of GVHD.

A commentary on the patient’s case and strategies for treatment selection and management for those with steroid-refractory disease.

Pashna Munshi, MD, provides an overview of adverse event data from the REACH3 trial of ruxolitinib in patients with steroid-refractory cGVHD and discusses management of patients’ side effects in clinical practice.

A comprehensive review of recent real-world ruxolitinib efficacy data and the use of emerging prognostic markers to risk-stratify patients with cGVHD.

Pashna Munshi, MD, expands upon ruxolitinib’s mechanism of action in steroid-refractory cGVHD and discusses REACH3 efficacy data.

A focused discussion on available treatment options for patients with steroid-refractory cGVHD.

Pashna Munshi, MD reviews risk factors for steroid-refractory cGVHD and the clinical challenges of identification, treatment, and management of the disease.

An overview of common symptoms, diagnostic challenges, and tools for severity assessment of chronic graft-versus-host disease.

Pashna Munshi, MD, discusses the treatment of a 58-year-old man who developed moderate steroid-refractory chronic graft-versus-host disease (cGVHD) after a stem cell transplant, and briefly reviews risk factors for developing cGVHD.

Samuel J. Klempner, MD, discusses unmet needs in patients with gastroesophageal adenocarcinoma when it comes to biomarker-targeted agents.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. An explanation of the role of BCL-2 family proteins in normal cells and in multiple myeloma-affected cells.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Jonathan Kaufman, MD, provides an overview of multiple myeloma, including prevalence and risk populations.

Tracy Rose, MD, discusses the promising outlook of the current bladder cancer space.

Rajneesh Nath, MD, discusses what is in store regarding treatment for elderly patients with relapsed/refractory acute myeloid leukemia.